New and novel pharmacotherapies for hemophilia A: an update
ABSTRACT Introduction Hemophilia A (HA) management has progressed significantly, yet standard and extended half-life (EHL) clotting factors present persistent limitations, including intravenous burden and suboptimal trough levels. Areas covered This narrative review highlights recently approved agents and phase III can...